Skip to content
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Pulmonology · Allergic Asthma

Biology and Diagnosis: How Allergic Asthma is Confirmed

At a Glance

Allergic asthma is diagnosed by symptoms plus evidence of changing airflow, usually from spirometry before and after a bronchodilator. If spirometry is normal, peak-flow monitoring, FeNO, or challenge testing may help. Allergy tests show sensitivity but do not prove which allergen causes symptoms.

While asthma may feel like a simple case of “tight lungs,” the allergic version is driven by a complex biological relay race. Understanding this process—and how doctors measure it—can help you make sense of why certain tests and treatments are chosen for you.

The Biology of an Allergic Flare

Allergic asthma is powered by Type 2 inflammation, a specific immune pathway designed to protect the body but which overreacts in people with asthma [1].

Plain language summary: When you breathe in an allergen, the lining of your lungs sounds an alarm. This alarm recruits immune cells and proteins that cause your body to produce allergic antibodies (IgE). These antibodies attach to sensitive cells in your airways. When the allergen appears again, these cells burst open, dumping chemicals that instantly tighten your airways and produce thick mucus.

For readers who want more molecular detail, this process involves several key “players” in your immune system:

  • Epithelial Alarmins: When you inhale an allergen, the lining of your lungs (the epithelium) releases “danger signals” called alarmins (such as TSLP, IL-25, and IL-33) [2][3]. These act like an alarm system that kicks the rest of the immune response into gear.
  • The Interleukin Messengers: These alarmins activate specialized cells that release messengers called interleukins [4]. IL-4 and IL-13 tell your body to produce more IgE (the allergic antibody) and cause your airways to produce excess mucus [5][6]. IL-5 acts as a recruiter for eosinophils, a type of white blood cell that causes deep tissue inflammation [7].
  • Mast Cells and Immediate Reaction: In your airways, IgE antibodies sit on the surface of mast cells [8]. When an allergen (like pollen) hits these cells, they “degranulate,” instantly dumping chemicals like histamine and leukotrienes [9]. This causes the rapid airway tightening (bronchoconstriction) you feel during a flare.

Over time, this chronic inflammation can lead to airway remodeling, where the lung walls become thicker and less flexible, making the asthma harder to treat [10][11].

The Gold Standard: Spirometry

Because asthma symptoms like coughing or wheezing can overlap with other conditions, doctors use objective tests to confirm the diagnosis. According to global guidelines (GINA and ERS), the first step is usually spirometry [12][13].

Asthma causes variable expiratory airflow obstruction, meaning it limits your ability to push air out of your lungs. During this test, you blow into a tube as hard and fast as you can to measure how much air your lungs can hold and how quickly you can exhale it. Doctors focus on the FEV1 (the amount of air you can force out in one second) [14].

  • Bronchodilator Reversibility: If your initial blow shows obstruction, you will be given a “rescue” inhaler and asked to wait 15 minutes before blowing again [12]. A significant improvement supports an asthma diagnosis. Traditionally in adults, this is defined as an increase in FEV1 of at least 12% and 200 mL, though exact criteria can vary by age and current testing guidelines [14][15].
  • Note on Negative Results: A “normal” spirometry result does not rule out asthma. If your symptoms were not active on the day of the test, your lungs might look normal even if you truly have asthma. Diagnosis combines characteristic variable symptoms with objective evidence [16][15].

When the First Test is Not Enough

If spirometry is normal but your symptoms persist, your doctor may use other tools to look for variable airflow limitation (the tendency of asthma to come and go) [12]:

  1. Peak Flow Variability: You may be asked to use a small handheld Peak Flow Meter at home twice a day for two weeks. If your scores vary significantly over time—according to the age-appropriate calculation method used by your clinic—it supports an asthma diagnosis [12][17].
  2. FeNO (Fractional Exhaled Nitric Oxide): This test measures how much nitric oxide gas is in your breath. High levels suggest that your airways are inflamed by the Type 2 pathway, but it does not definitively diagnose allergic asthma [18][19]. FeNO is particularly useful for deciding if you will respond well to steroid treatments [18].
  3. Bronchial Challenge Tests: In a specialized clinic, you might be asked to inhale a substance like methacholine or mannitol that causes temporary, mild airway narrowing in people with sensitive lungs [12][20]. If your lungs react to very low doses, it confirms that your airways are “hyperresponsive” [21].

Confirming the “Allergic” Piece

Once asthma is confirmed, tests are used to identify your specific triggers (phenotyping) [18].

  • Skin-Prick Testing: Small amounts of allergens are placed on your skin. If a small, itchy bump (wheal) appears, you are sensitized to that substance [22].
  • Blood Tests (Specific IgE): This measures the exact amount of IgE your blood produces for specific allergens [23].
  • Total IgE and Eosinophils: A simple blood draw can check your eosinophils and measure your total IgE level [18][24]. Total IgE is a marker of Type 2 inflammation, but it is not a direct measure of asthma severity or “allergic burden.”

It is important to remember that having a positive allergy test does not always mean that substance is causing your asthma; it only proves sensitization. Your doctor will compare your test results to your real-world symptoms to determine which triggers actually matter for your care, as results are affected by inhaled steroids, smoking, and other conditions [23].

Common questions in this guide

How do doctors confirm allergic asthma?
Doctors compare your pattern of symptoms with objective breathing tests, usually spirometry. Improvement in airflow after a bronchodilator supports asthma, while skin or blood allergy tests help identify sensitivity to particular allergens; those tests do not by themselves prove which trigger causes your symptoms.
What does spirometry show if I have asthma?
Spirometry measures how much air you can force out in one second and how quickly you exhale. Asthma may show variable blockage of airflow, and a meaningful rise in FEV1 after a bronchodilator supports the diagnosis. In adults, the traditional threshold is at least a 12% and 200 mL increase, although criteria can vary.
Can I still have allergic asthma if my spirometry is normal?
Yes. Asthma symptoms and airway narrowing can vary, so the test may be normal when symptoms are quiet. Your clinician may consider two weeks of peak-flow readings, FeNO, or a bronchial challenge test to look for changing or overly sensitive airways.
What does a high FeNO result mean?
FeNO measures nitric oxide in your exhaled breath. A high result suggests inflammation involving the Type 2 immune pathway and may help predict a response to inhaled steroids, but it does not by itself confirm allergic asthma.
Do positive allergy tests prove which allergen causes my asthma?
No. A positive skin-prick or specific IgE blood test shows that your immune system is sensitized to an allergen. Your clinician must compare that result with when and where your symptoms occur to decide whether the allergen is a meaningful asthma trigger.
What should I tell my doctor before asthma or allergy testing?
Tell your clinician about antihistamines, inhaled steroids, other medicines, and smoking. These factors can affect the accuracy or interpretation of some breathing and allergy tests, so do not stop a medicine unless your clinician tells you to.

Get notified when new evidence is published on extrinsic asthma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (24)
  1. 1

    How type-2 dendritic cells induce Th2 differentiation: Instruction, repression, or fostering T cell-T cell communication?

    Ronchese F, Webb GR, Ochiai S, et al.

    Allergy 2025; (80(2)):395-407 doi:10.1111/all.16337.

    PMID: 39324367
  2. 2

    Anti-alarmin approaches entering clinical trials.

    Gauvreau GM, White L, Davis BE

    Current opinion in pulmonary medicine 2020; (26(1)):69-76 doi:10.1097/MCP.0000000000000615.

    PMID: 31408015
  3. 3

    The Therapeutic Potential for Targeting Group 2 Innate Lymphoid Cells in Asthma.

    Matsuyama T, Matsuyama H, Dotake Y, et al.

    Frontiers in immunology 2022; (13()):930862 doi:10.3389/fimmu.2022.930862.

    PMID: 35911708
  4. 4

    Epithelial cell-derived cytokines: more than just signaling the alarm.

    Roan F, Obata-Ninomiya K, Ziegler SF

    The Journal of clinical investigation 2019; (129(4)):1441-1451.

    PMID: 30932910
  5. 5

    The Possible Roles of IL-4/IL-13 in the Development of Eosinophil-Predominant Severe Asthma.

    Nakagome K, Nagata M

    Biomolecules 2024; (14(5)) doi:10.3390/biom14050546.

    PMID: 38785953
  6. 6

    T-helper cells and their cytokines in pathogenesis and treatment of asthma.

    Ji T, Li H

    Frontiers in immunology 2023; (14()):1149203 doi:10.3389/fimmu.2023.1149203.

    PMID: 37377958
  7. 7

    Type 2 immunity in the skin and lungs.

    Akdis CA, Arkwright PD, Brüggen MC, et al.

    Allergy 2020; (75(7)):1582-1605 doi:10.1111/all.14318.

    PMID: 32319104
  8. 8

    Therapeutic monoclonal antibodies in allergy: Targeting IgE, cytokine, and alarmin pathways.

    Eggel A, Pennington LF, Jardetzky TS

    Immunological reviews 2024; (328(1)):387-411 doi:10.1111/imr.13380.

    PMID: 39158477
  9. 9

    Airway hyperresponsiveness in asthma: The role of the epithelium.

    Bradding P, Porsbjerg C, Côté A, et al.

    The Journal of allergy and clinical immunology 2024; (153(5)):1181-1193 doi:10.1016/j.jaci.2024.02.011.

    PMID: 38395082
  10. 10

    Targeting IL-13 and IL-4 in Asthma: Therapeutic Implications on Airway Remodeling in Severe Asthma.

    Sahnoon L, Bajbouj K, Mahboub B, et al.

    Clinical reviews in allergy & immunology 2025; (68(1)):44 doi:10.1007/s12016-025-09045-2.

    PMID: 40257546
  11. 11

    Pathogenic group 2 innate lymphoid cells as drivers of lung fibrosis in severe asthma.

    Matsuda M, Sannomiya Y, Kaminuma O, Nabe T

    Frontiers in immunology 2026; (17()):1957593 doi:10.3389/fimmu.2026.1957593.

    PMID: 42712896
  12. 12

    European Respiratory Society guidelines for the diagnosis of asthma in adults.

    Louis R, Satia I, Ojanguren I, et al.

    The European respiratory journal 2022; (60(3)) doi:10.1183/13993003.01585-2021.

    PMID: 35169025
  13. 13

    Asthma diagnosis in adults and children: challenges, future directions, and a call to action.

    Hassan W, Wang R, Mohammedalhadi A, et al.

    The Lancet. Respiratory medicine 2026; doi:10.1016/S2213-2600(26)00143-8.

    PMID: 42409035
  14. 14

    Clinical value of bronchodilator response for diagnosing asthma in steroid-naïve adults.

    Tuomisto LE, Ilmarinen P, Lehtimäki L, et al.

    ERJ open research 2021; (7(4)) doi:10.1183/23120541.00293-2021.

    PMID: 34912880
  15. 15

    Asthma diagnosis: a comparison of established diagnostic guidelines in adults with respiratory symptoms.

    Simpson AJ, Drake S, Healy L, et al.

    EClinicalMedicine 2024; (76()):102813 doi:10.1016/j.eclinm.2024.102813.

    PMID: 39296585
  16. 16

    Performance Characteristics of Spirometry With Negative Bronchodilator Response and Methacholine Challenge Testing and Implications for Asthma Diagnosis.

    Selvanathan J, Aaron SD, Sykes JR, et al.

    Chest 2020; (158(2)):479-490 doi:10.1016/j.chest.2020.03.052.

    PMID: 32298731
  17. 17

    What is the Best Way to Diagnose Possible Asthma Patients with Negative Bronchodilator Reversibility Tests?

    Başa Akdoğan B, Koca Kalkan I, Köycü Buhari G, et al.

    Journal of asthma and allergy 2024; (17()):113-122 doi:10.2147/JAA.S437756.

    PMID: 38410137
  18. 18

    Dupilumab Is Effective in Patients With Moderate-to-Severe Uncontrolled GINA-Defined Type 2 Asthma Irrespective of an Allergic Asthma Phenotype.

    Rabe KF, FitzGerald JM, Bateman ED, et al.

    The journal of allergy and clinical immunology. In practice 2022; (10(11)):2916-2924.e4 doi:10.1016/j.jaip.2022.06.036.

    PMID: 36028446
  19. 19

    Biomarkers in pediatric asthma: clinical maturity, intended use, and future directions.

    Fujisawa T, Iwai F

    Allergology international : official journal of the Japanese Society of Allergology 2026; (75(4)):529-537 doi:10.1016/j.alit.2026.08.003.

    PMID: 42642256
  20. 20

    Airway Hyperresponsiveness in Asthma: Measurement and Clinical Relevance.

    Nair P, Martin JG, Cockcroft DC, et al.

    The journal of allergy and clinical immunology. In practice 2017; (5(3)):649-659.e2 doi:10.1016/j.jaip.2016.11.030.

    PMID: 28163029
  21. 21

    ERS technical standard on bronchial challenge testing: pathophysiology and methodology of indirect airway challenge testing.

    Hallstrand TS, Leuppi JD, Joos G, et al.

    The European respiratory journal 2018; (52(5)) doi:10.1183/13993003.01033-2018.

    PMID: 30361249
  22. 22

    How can we improve our use of allergen immunotherapy as a treatment option for asthma and severe asthma?

    Larenas-Linnemann D, Morfin Maciel BM

    Expert review of respiratory medicine 2023; (17(8)):717-725 doi:10.1080/17476348.2023.2251403.

    PMID: 37642332
  23. 23

    Allergic Asthma in the Era of Personalized Medicine.

    Papapostolou N, Makris M

    Journal of personalized medicine 2022; (12(7)) doi:10.3390/jpm12071162.

    PMID: 35887659
  24. 24

    Relationship between total serum immunoglobulin E levels, fractional exhaled breath nitric oxide levels and absolute blood eosinophil counts in atopic and non-atopic asthma: a controlled comparative study.

    Shrestha SK, Drews A, Sharma L, et al.

    Journal of breath research 2018; (12(2)):026009 doi:10.1088/1752-7163/aa95da.

    PMID: 29068321

This page explains how allergic asthma is evaluated for informational purposes only and does not constitute medical advice. Your clinician should interpret your breathing, allergy, and inflammation test results in the context of your symptoms.